A major Melbourne study is tracking thousands of children to determine whether vitamin D in the first year of life can reduce food allergy and reveal how early immune development shapes later health.
Australia’s high burden of food allergy has made it an important testing ground for prevention research, and a long-running Melbourne study is now offering one of the most detailed attempts yet to answer a simple question: can giving babies vitamin D in the first year of life reduce the risk of allergy later on? Public health figures cited by the Australian Parliament and the Australasian Society of Clinical Immunology and Allergy suggest food allergy affects about one in 10 infants in Australia, while more recent national survey data published in 2026 found that seven per cent of Australians overall report food allergies, underscoring how widely allergic disease continues to affect the population.
The VITALITY study, based in Melbourne, was designed to test that idea under rigorous trial conditions. It enrolled healthy, term babies who were not already receiving vitamin D, then assigned them to either a daily 400 International Units dose of vitamin D3 or an identical placebo from early infancy until 12 months of age. Researchers set out to measure whether supplementation reduced food allergy confirmed by clinical testing, rather than relying on parental report or less precise indicators. The trial was also built as a longitudinal cohort, so the same children could later be followed for asthma, eczema, infections and other immune-related outcomes.
The scale of the project sets it apart. According to the report on VITALITY, more than 13,500 infants were approached across greater Melbourne, 2,739 were randomly assigned and retention remained strong even through the COVID-19 pandemic. The study team shifted from clinic-based recruitment to social media when lockdowns disrupted face-to-face contact, helping maintain enrolment despite months of restrictions. At the 12-month visit, thousands of babies underwent skin prick testing and many went on to supervised oral food challenges, the clinical gold standard for diagnosing true food allergy.
What makes the study especially valuable is the amount of biological and environmental detail it collected. Blood samples, stool, breast milk and skin swabs were banked for later analysis, alongside questionnaires covering feeding, home exposures and factors that might shape vitamin D status. The investigators also used advanced laboratory methods to measure vitamin D levels and preserve immune cells for later study. The article describing the cohort says the resulting biobank spans blood, gut, skin and breast-milk samples, creating a resource that could help researchers examine the links between early nutrition, the microbiome and allergic disease for years to come.
The study’s follow-up is extending into school age, reflecting growing interest in whether infant allergy is tied to later lung function and asthma. That matters in Australia, where allergic disease is now considered a major and enduring public health problem, with the parliamentary committee warning of a rising social and economic burden. Earlier research has not provided a clear answer: one prior randomised trial of maternal vitamin D during lactation suggested the supplement may not protect against eczema and could be linked with more later food allergy, which is one reason the VITALITY trial has attracted so much attention. The Melbourne study’s value, however, may end up going beyond vitamin D itself, because its design gives researchers a rare platform for studying immune development in early life with objective clinical outcomes and linked health records.
Disclaimer: This content is for informational purposes only and is not intended to be a substitute for professional medical judgment, advice, diagnosis, or treatment.
